Ambev S.A. (ABEV)

Ligand Pharmaceuticals Stock Forecast

Stock Price Forecast

The 2 analysts that cover Ligand Pharmaceuticals stock have a consensus rating of "Hold" and an average price target of $2.60, which forecasts a 19.54% increase in the stock price over the next year. The lowest target is $2.50 and the highest is $2.70.

Price Target: $2.60 (+19.54%)

Analyst Consensus: Hold

Target	Low	Average	Median	High
Price	$2.50	$2.60	$2.70	$2.70
Change	+14.94%	+19.54%	+24.14%	+24.14%

* Price targets were last updated on Jun 4, 2025.

Analyst Ratings

The average analyst rating for Ligand Pharmaceuticals stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.

Recommendation Trends

Rating	Feb '25	Mar '25	Apr '25	May '25	Jun '25	Jul '25
Strong Buy	0	1	0	0	0	0
Buy	0	0	0	0	0	0
Hold	2	2	3	3	3	3
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	2	3	3	3	3	3

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Rodrigo Alcantara UBS	UBS	Hold Maintains $2.6 → $2.7	Hold	Maintains	$2.6 → $2.7	+24.14%	Jun 4, 2025
Benjamin Theurer Barclays	Barclays	Hold Maintains $2 → $2.5	Hold	Maintains	$2 → $2.5	+14.94%	May 12, 2025
Rodrigo Alcantara UBS	UBS	Strong Buy → Hold Downgrades n/a	Strong Buy → Hold	Downgrades	n/a	n/a	Apr 22, 2025
Rodrigo Alcantara UBS	UBS	Strong Buy Maintains $2.9 → $2.6	Strong Buy	Maintains	$2.9 → $2.6	+19.54%	Mar 5, 2025
Renata Cabral Citigroup	Citigroup	Strong Buy → Hold Downgrades n/a	Strong Buy → Hold	Downgrades	n/a	n/a	Jan 22, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

97.56B

Increased by 9.06%

from 89.45B

Revenue Next Year

102.63B

Increased by 5.19%

from 97.56B

EPS This Year

1.03

Increased by 12.75%

from 0.91

EPS Next Year

1.08

Increased by 5.31%

from 1.03

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	58.38B	72.85B	79.71B	79.74B	89.45B	97.56B	102.63B	107.95B
Revenue Growth	12.26%	24.80%	9.41%	0.03%	12.19%	9.06%	5.19%	5.18%
EPS	0.72	0.80	0.91	0.92	0.91	1.03	1.08	1.17
EPS Growth	-3.39%	11.42%	14.17%	0.36%	-0.30%	12.75%	5.31%	8.10%
Forward PE	-	-	-	-	-	11.71	11.12	10.29
No. Analysts	-	-	-	-	-	15	14	12

Financial currency is BRL. Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027	2028	2029
High	101.0B	107.7B	113.2B
Avg	97.6B	102.6B	107.9B
Low	89.4B	94.4B	98.8B

Revenue Growth

Revenue Growth	2025	2026	2027	2028	2029
High	12.9%	10.4%	10.3%
Avg	9.1%	5.2%	5.2%
Low	-0.0%	-3.2%	-3.7%

EPS Forecast

EPS	2025	2026	2027	2028	2029
High	1.10	1.23	1.32
Avg	1.03	1.08	1.17
Low	0.90	0.91	0.93

EPS Growth

EPS Growth	2025	2026	2027	2028	2029
High	20.8%	19.4%	22.1%
Avg	12.8%	5.3%	8.1%
Low	-1.2%	-11.5%	-14.1%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.